Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients Wirh Advanced Liver Tumors
Latest Information Update: 08 Sep 2023
At a glance
- Drugs IM 83 chimeric antigen receptor T cell therapy-Beijing Immunochina Medical Science and Technology (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Beijing Immunochina Medical Science and Technology
- 19 Nov 2021 New trial record